Obiettivo Degenerative diseases of old age, including cardiovascular diseases, type II diabetes, and chronic respiratory conditions, have emerged as the major causes of death in EU countries. Of special concern are neurodegenerative conditions including Alzheimer’s and Parkinson’s, which have been described as the greatest unmet need facing modern medicine. Developing new therapies to slow, halt, or reverse these pathologies is regarded as a key element in addressing this global health priority. No such therapies have been successfully developed to date.A major unsolved challenge faced by drug discovery organisations is that for most degenerative conditions, there are no prognostic markers that can be used to predict whether a candidate therapy is likely to improve clinical outcome.Our solution to this problem exploits the fact that the pathogenesis and progression of all degenerative diseases is associated with oxidative stress. Oxidative stress thus makes an excellent potential prognostic biomarker, but it has been difficult to measure in vivo. Now, under the REDOX ERC Advanced Investigator Award, we have developed a portfolio of next-generation mouse models in which oxidative stress can be monitored at single-cell resolution across all organs. Moreover, the measurements can also be performed non-invasively and in real-time. We believe that these mice provides a new platform with unprecedented utility that can be used by drug-discovery organisations to accelerate, reduce the costs, and increase the predictive power of their pre-clinical pipelines for degenerative conditions. To support commercial exploitation of these models, we will:a) Show that our oxidative stress biomarkers are elevated in mouse models for two degenerative conditions, Alzheimer’s and Hutchinson-Gilford Progeria Syndrome.b) Demonstrate that the biomarker signals are reduced in mice administered therapies believed to be disease-modifying. Campo scientifico scienze mediche e della salutemedicina di basefarmacologia e farmaciascoperta di farmaciscienze mediche e della salutemedicina di baseneurologiademenzaalzheimerscienze mediche e della salutemedicina clinicaendocrinologiadiabetescienze mediche e della salutemedicina clinicacardiologiamalattie cardiovascolariscienze mediche e della salutemedicina di baseneurologiaparkinson Programma(i) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Argomento(i) ERC-PoC-2016 - ERC-Proof of Concept-2016 Invito a presentare proposte ERC-2016-PoC Vedi altri progetti per questo bando Meccanismo di finanziamento ERC-POC - Proof of Concept Grant Coordinatore UNIVERSITY OF DUNDEE Contribution nette de l'UE € 149 961,00 Indirizzo Nethergate DD1 4HN Dundee Regno Unito Mostra sulla mappa Regione Scotland Eastern Scotland Angus and Dundee City Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Altri finanziamenti € 0,00 Beneficiari (1) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto UNIVERSITY OF DUNDEE Regno Unito Contribution nette de l'UE € 149 961,00 Indirizzo Nethergate DD1 4HN Dundee Mostra sulla mappa Regione Scotland Eastern Scotland Angus and Dundee City Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Altri finanziamenti € 0,00
